What is FoundationOne Heme?
FoundationOne Heme is a comprehensive genomic profiling (CGP) test combining DNA and RNA sequencing for patients with hematologic malignancies, sarcomas or solid tumors where RNA sequencing is desired. FoundationOne Heme detects known, novel, and complex fusion events as well as other common genomic alterations (substitutions, indels, and CNVs). This laboratory developed test (LDT) can be used by physicians to identify potential targeted therapy options, detect alterations in prognostic genes, and sub-classify sarcoma diagnoses.
>400 DNA-sequenced genes and >250 RNA-sequenced genes
Combines DNA and RNA sequencing to detect all four main classes of genomic alterations, including sensitive identification of translocations and fusions
Valuable insights to help guide treatment strategies
Expansive gene panel provides broad coverage across guideline-recommended genes in leukemias and MDS.¹⁻³
Multiple sample types accepted
FoundationOne Heme is validated for FFPE tissue, peripheral whole blood, bone marrow aspirate, and extracted nucleic acid
FAQ and Resources
FoundationOne Heme Resources
ResourcesView Additional Resources
Learn more about the clinical utility of FoundationOne Heme in a number of cancer types.
FoundationOne Heme Acute Myeloid Leukemia (AML) Sample ReportDOWNLOAD SAMPLE REPORT
View a FoundationOne Heme AML sample report. This report shows results with an IDH2 and TET2 alteration detected.
Can Rapid Precision Medicine Help Older Adults With AML?READ FULL BLOG POST
The findings from the Beat AML Master trial offer new insights that, we believe, can help change clinical practice because they validate a framework for rapid precision medicine that improves outcome. Because blood cancers are so complex, they require a sophisticated strategy to understand each patient’s unique cancer as well as the treatments that have the best chance at improving survival.
FoundationOne Heme Acute B-Lymphocytic Leukemia (B-ALL) Sample ReportDOWNLOAD SAMPLE REPORT
View a FoundationOne Heme B-ALL sample report. This report shows results with an ABL1 alteration detected.
Genomic Landscape of Adult and Pediatric BCR‐ABL1 ‐Like B‐Lymphoblastic Leukemia Using Parallel DNA and RNA SequencingVIEW PUBLICATION
Comprehensive genomic profiling performed on 450 patients with extensive fusion profiling revealed a wide range of genomic alterations which were consistent with a classification of BCR‐ABL1‐like B‐ALL in 29% of cases.
FoundationOne Heme Sarcoma Sample ReportDOWNLOAD SAMPLE REPORT
View a FoundationOne Heme Sarcoma sample report. This report shows results that include elevated TMB, high-MSI status, and an NTRK1 rearrangement detected.
CTOS 2019: Navigating the sarcoma maze with CGPREAD FULL BLOG POST
With more than 80 subtypes, sarcomas can be susceptible to misdiagnosis, and there are very limited treatment guidelines beyond standard chemotherapy.4 This is where comprehensive genomic profiling (CGP) can help remove the guess work by identifying alterations in the genes driving the cancer that might be prognostic or inform targeted therapies.
Need More Details?
Our client services team is here to help, Monday through Friday 8AM – 8PM EST.
NCCN makes no warranties of any kind whatsoever regarding their content, use or application and disclaims any responsibility for their application or use in any way.
1Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Myeloid Leukemia V.3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.
2Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Acute Lymphoblastic Leukemia V.1.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.
3Referenced with permission from the NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) for Myelodysplastic Syndromes V.3.2021. © National Comprehensive Cancer Network, Inc. 2021. All rights reserved. Accessed April 30, 2021. To view the most recent and complete version of the guideline, go online to NCCN.org.
4Casali, et al. Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment, and follow-up. Annals of Oncology. 2018;29(Supp 4):iv51-iv67. doi:10.1093/annonc/mdy096.
FoundationOne Heme was developed and its performance characteristics determined by Foundation Medicine. It has not been cleared or approved by the U.S. Food and Drug Administration. For more information on our laboratory developed test (LDT) please see the Technical Specifications at www.foundationmedicine.com.